Celsion Co. (NASDAQ:CLSN) has been assigned an average rating of “Buy” from the six research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $14.50.

Several analysts have weighed in on the company. Zacks Investment Research cut Celsion from a “buy” rating to a “hold” rating in a report on Tuesday, October 17th. ValuEngine raised Celsion from a “strong sell” rating to a “sell” rating in a report on Saturday, December 9th. Finally, Oppenheimer assumed coverage on Celsion in a report on Tuesday, November 21st. They set an “outperform” rating and a $9.00 price objective for the company.

Celsion (NASDAQ CLSN) traded down $0.01 during trading on Friday, hitting $2.20. The company had a trading volume of 25,034 shares, compared to its average volume of 453,341. Celsion has a fifty-two week low of $1.24 and a fifty-two week high of $7.56. The company has a market capitalization of $37.10, a PE ratio of -0.38 and a beta of 1.82.

Celsion (NASDAQ:CLSN) last announced its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.39) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.56) by $0.17. The firm had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $0.13 million. Celsion had a negative return on equity of 282.94% and a negative net margin of 4,292.80%. analysts forecast that Celsion will post -2.46 EPS for the current fiscal year.

An institutional investor recently bought a new position in Celsion stock. Sabby Management LLC acquired a new position in shares of Celsion Co. (NASDAQ:CLSN) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 108,843 shares of the biotechnology company’s stock, valued at approximately $223,000. Sabby Management LLC owned about 1.30% of Celsion at the end of the most recent quarter. 4.01% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.dailypolitical.com/2018/02/07/celsion-co-clsn-receives-14-50-consensus-price-target-from-analysts.html.

Celsion Company Profile

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.